Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pseudomonas Phages | 2 | 2021 | 9 | 0.910 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2014 | 147 | 0.810 |
Why?
|
| Sewage | 2 | 2021 | 8 | 0.780 |
Why?
|
| beta-Lactamases | 4 | 2020 | 198 | 0.780 |
Why?
|
| Rivers | 2 | 2021 | 9 | 0.780 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 306 | 0.760 |
Why?
|
| Klebsiella Infections | 2 | 2018 | 54 | 0.720 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2020 | 133 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 2106 | 0.610 |
Why?
|
| Embolism | 1 | 2018 | 48 | 0.570 |
Why?
|
| Klebsiella pneumoniae | 1 | 2018 | 76 | 0.570 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 72 | 0.560 |
Why?
|
| Iran | 11 | 2024 | 88 | 0.540 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 139 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 8 | 2024 | 2430 | 0.520 |
Why?
|
| Intensive Care Units | 2 | 2024 | 493 | 0.500 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2024 | 797 | 0.440 |
Why?
|
| Microbiota | 3 | 2024 | 389 | 0.430 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 635 | 0.430 |
Why?
|
| Phage Therapy | 3 | 2024 | 33 | 0.430 |
Why?
|
| Heart Ventricles | 1 | 2018 | 770 | 0.420 |
Why?
|
| Veins | 1 | 2013 | 108 | 0.410 |
Why?
|
| Whole Body Imaging | 1 | 2013 | 29 | 0.410 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 115 | 0.410 |
Why?
|
| Colistin | 2 | 2022 | 30 | 0.360 |
Why?
|
| Helicobacter pylori | 4 | 2019 | 1324 | 0.360 |
Why?
|
| Pseudomonas Infections | 2 | 2021 | 114 | 0.330 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 365 | 0.330 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2024 | 222 | 0.330 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 737 | 0.330 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2021 | 164 | 0.320 |
Why?
|
| Probiotics | 2 | 2023 | 214 | 0.310 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 425 | 0.300 |
Why?
|
| Staphylococcal Infections | 3 | 2024 | 561 | 0.300 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 61 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 3 | 2024 | 1585 | 0.280 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 702 | 0.280 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 800 | 0.250 |
Why?
|
| Staphylococcal Protein A | 1 | 2024 | 7 | 0.240 |
Why?
|
| Integrons | 1 | 2024 | 1 | 0.230 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2024 | 8 | 0.230 |
Why?
|
| Organometallic Compounds | 2 | 2015 | 110 | 0.230 |
Why?
|
| Bacterial Proteins | 4 | 2024 | 890 | 0.220 |
Why?
|
| Surgical Wound | 1 | 2024 | 23 | 0.220 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3429 | 0.210 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2024 | 87 | 0.210 |
Why?
|
| Humans | 38 | 2024 | 125167 | 0.210 |
Why?
|
| Fibroblasts | 1 | 2007 | 878 | 0.210 |
Why?
|
| Nanotubes, Carbon | 1 | 2023 | 19 | 0.210 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 221 | 0.200 |
Why?
|
| Metal Nanoparticles | 1 | 2023 | 42 | 0.200 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 54 | 0.200 |
Why?
|
| Complementary Therapies | 1 | 2023 | 41 | 0.200 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 314 | 0.190 |
Why?
|
| Mouth | 1 | 2022 | 62 | 0.190 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 548 | 0.190 |
Why?
|
| Cross Infection | 1 | 2024 | 325 | 0.180 |
Why?
|
| Host Specificity | 1 | 2021 | 18 | 0.180 |
Why?
|
| Environmental Microbiology | 1 | 2021 | 16 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2024 | 308 | 0.180 |
Why?
|
| Apoptosis | 1 | 2007 | 1806 | 0.180 |
Why?
|
| Lactobacillus plantarum | 1 | 2020 | 3 | 0.170 |
Why?
|
| Tonsillitis | 1 | 2020 | 13 | 0.170 |
Why?
|
| Helicobacter Infections | 3 | 2019 | 1267 | 0.170 |
Why?
|
| Palatine Tonsil | 1 | 2020 | 36 | 0.170 |
Why?
|
| Genome, Viral | 1 | 2021 | 168 | 0.170 |
Why?
|
| Burns | 1 | 2021 | 77 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1026 | 0.170 |
Why?
|
| Mesentery | 1 | 2020 | 27 | 0.170 |
Why?
|
| Mesenteric Veins | 1 | 2020 | 16 | 0.170 |
Why?
|
| Adult | 16 | 2022 | 29634 | 0.170 |
Why?
|
| Mesenteric Ischemia | 1 | 2020 | 30 | 0.170 |
Why?
|
| Radial Artery | 1 | 2019 | 28 | 0.160 |
Why?
|
| Acinetobacter Infections | 1 | 2020 | 26 | 0.160 |
Why?
|
| Recombination, Genetic | 1 | 2021 | 447 | 0.160 |
Why?
|
| Acinetobacter baumannii | 1 | 2020 | 37 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 265 | 0.160 |
Why?
|
| Oxazolidinones | 1 | 2019 | 33 | 0.160 |
Why?
|
| Middle Aged | 16 | 2020 | 26932 | 0.160 |
Why?
|
| Male | 19 | 2024 | 61503 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 69 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 188 | 0.160 |
Why?
|
| Leiomyoma | 1 | 2019 | 81 | 0.160 |
Why?
|
| Neoplasms | 1 | 2013 | 2794 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2019 | 119 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 375 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2019 | 194 | 0.150 |
Why?
|
| Colitis | 1 | 2020 | 151 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 199 | 0.150 |
Why?
|
| Nalidixic Acid | 1 | 2018 | 3 | 0.150 |
Why?
|
| Clavulanic Acid | 1 | 2018 | 6 | 0.150 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 104 | 0.150 |
Why?
|
| Adhesins, Bacterial | 1 | 2019 | 75 | 0.150 |
Why?
|
| Imipenem | 1 | 2018 | 9 | 0.150 |
Why?
|
| Stomach Diseases | 1 | 2019 | 56 | 0.150 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 462 | 0.150 |
Why?
|
| Venous Cutdown | 1 | 2018 | 2 | 0.150 |
Why?
|
| Klebsiella | 1 | 2018 | 9 | 0.150 |
Why?
|
| Aged | 10 | 2024 | 19871 | 0.150 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 125 | 0.150 |
Why?
|
| Femoral Vein | 1 | 2018 | 51 | 0.140 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 155 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 218 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 382 | 0.140 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2018 | 60 | 0.140 |
Why?
|
| Amoxicillin | 1 | 2018 | 121 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 238 | 0.140 |
Why?
|
| Contrast Media | 1 | 2020 | 480 | 0.130 |
Why?
|
| Germanium | 1 | 2015 | 1 | 0.130 |
Why?
|
| Radiochemistry | 1 | 2015 | 3 | 0.130 |
Why?
|
| Escherichia coli | 2 | 2023 | 985 | 0.120 |
Why?
|
| Radioisotopes | 1 | 2015 | 39 | 0.120 |
Why?
|
| Mental Disorders | 1 | 2023 | 826 | 0.120 |
Why?
|
| Plasmids | 1 | 2016 | 513 | 0.120 |
Why?
|
| Bacteria | 3 | 2024 | 484 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2020 | 478 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2015 | 135 | 0.120 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 123 | 0.120 |
Why?
|
| Female | 19 | 2020 | 66783 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 1105 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2021 | 1502 | 0.110 |
Why?
|
| Saliva | 2 | 2005 | 114 | 0.110 |
Why?
|
| Octreotide | 1 | 2014 | 23 | 0.110 |
Why?
|
| Digestive System Neoplasms | 1 | 2014 | 14 | 0.110 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 54 | 0.110 |
Why?
|
| Prevalence | 4 | 2024 | 2456 | 0.110 |
Why?
|
| Phlebography | 1 | 2013 | 50 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 54 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 168 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 1896 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6600 | 0.100 |
Why?
|
| Nitric Oxide | 2 | 2005 | 493 | 0.100 |
Why?
|
| Nasal Polyps | 1 | 2011 | 25 | 0.090 |
Why?
|
| Urease | 1 | 2011 | 73 | 0.090 |
Why?
|
| Nasal Mucosa | 1 | 2011 | 66 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 12394 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2013 | 1506 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 350 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1276 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2005 | 838 | 0.080 |
Why?
|
| Adolescent | 5 | 2020 | 19350 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3572 | 0.080 |
Why?
|
| Cystic Duct | 1 | 2008 | 1 | 0.080 |
Why?
|
| Phylogeny | 2 | 2021 | 696 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2022 | 3300 | 0.070 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 44 | 0.070 |
Why?
|
| Densitometry | 1 | 2007 | 25 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2007 | 311 | 0.070 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 35 | 0.070 |
Why?
|
| Species Specificity | 1 | 2007 | 550 | 0.070 |
Why?
|
| Olfaction Disorders | 1 | 2006 | 28 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 110 | 0.070 |
Why?
|
| Genes, Recessive | 1 | 2007 | 185 | 0.060 |
Why?
|
| Calcium Phosphates | 1 | 2006 | 8 | 0.060 |
Why?
|
| Urinary Calculi | 1 | 2006 | 18 | 0.060 |
Why?
|
| Calcium Oxalate | 1 | 2006 | 24 | 0.060 |
Why?
|
| Melanoma | 1 | 2013 | 943 | 0.060 |
Why?
|
| Risk | 1 | 2007 | 756 | 0.060 |
Why?
|
| Proteinuria | 1 | 2006 | 102 | 0.060 |
Why?
|
| Pentoxifylline | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2007 | 143 | 0.060 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 139 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 1271 | 0.060 |
Why?
|
| Mutation | 3 | 2023 | 5842 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 9056 | 0.050 |
Why?
|
| Allopurinol | 1 | 2004 | 71 | 0.050 |
Why?
|
| Genes, Bacterial | 1 | 2024 | 211 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1660 | 0.050 |
Why?
|
| Electrochemical Techniques | 1 | 2023 | 6 | 0.050 |
Why?
|
| Bone Density | 1 | 2005 | 319 | 0.050 |
Why?
|
| Gold | 1 | 2023 | 48 | 0.050 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 369 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 14019 | 0.050 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2022 | 32 | 0.050 |
Why?
|
| Laboratories | 1 | 2023 | 81 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 79 | 0.050 |
Why?
|
| Biopsy | 2 | 2019 | 1237 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2023 | 92 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2024 | 260 | 0.050 |
Why?
|
| Genotyping Techniques | 1 | 2021 | 103 | 0.050 |
Why?
|
| Child | 2 | 2018 | 24402 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 321 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3348 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2020 | 89 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2020 | 47 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-gamma | 1 | 2019 | 4 | 0.040 |
Why?
|
| Carbapenems | 1 | 2020 | 36 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 6334 | 0.040 |
Why?
|
| Punctures | 1 | 2019 | 55 | 0.040 |
Why?
|
| Haplotypes | 1 | 2021 | 522 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2020 | 87 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2019 | 61 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2019 | 140 | 0.040 |
Why?
|
| Coinfection | 1 | 2021 | 171 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 537 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2019 | 244 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2019 | 90 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2019 | 185 | 0.040 |
Why?
|
| Interleukins | 1 | 2019 | 120 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2019 | 153 | 0.040 |
Why?
|
| Superantigens | 1 | 2018 | 20 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2019 | 209 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 215 | 0.040 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 23 | 0.040 |
Why?
|
| Enterotoxins | 1 | 2018 | 82 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 264 | 0.040 |
Why?
|
| Genotype | 2 | 2019 | 2564 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 652 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 998 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 666 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1396 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 350 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2020 | 16342 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 175 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 506 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 814 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 270 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 777 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2008 | 3071 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1288 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1195 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 34219 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2893 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 1398 | 0.030 |
Why?
|
| Ion Exchange | 1 | 2015 | 5 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 7 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 2 | 2005 | 19 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 274 | 0.030 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 97 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 2999 | 0.030 |
Why?
|
| Vaccines | 1 | 2019 | 365 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 189 | 0.030 |
Why?
|
| Bacteremia | 1 | 2018 | 406 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 272 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 17632 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1056 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2005 | 1637 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 5177 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4392 | 0.020 |
Why?
|
| Cholangiography | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2008 | 12 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 2008 | 16 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2174 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2064 | 0.020 |
Why?
|
| Vestibule, Labyrinth | 1 | 2007 | 43 | 0.020 |
Why?
|
| Thyroxine | 1 | 2007 | 66 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3054 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3588 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2005 | 17 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 10309 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 54 | 0.020 |
Why?
|
| Femur | 1 | 2005 | 67 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2005 | 54 | 0.010 |
Why?
|
| Postmenopause | 1 | 2005 | 126 | 0.010 |
Why?
|
| Quality of Life | 1 | 2014 | 1940 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2005 | 117 | 0.010 |
Why?
|
| Syndrome | 1 | 2007 | 1120 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 3146 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 716 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 613 | 0.010 |
Why?
|
| Metformin | 1 | 2005 | 151 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 313 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 589 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 444 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 1565 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 2913 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 4642 | 0.010 |
Why?
|